Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Backs Off From Early Citations Of Compounder Sterility Issues

Executive Summary

A month after compounding pharmacists' latest annual visit to Congress, FDA has acted on one of their chief complaints – investigators citing them for GMP violations even in cases where the agency later acknowledged they were exempt.

Advertisement

Related Content

FDA GMP Warning Letters Review: Compounding Pharmacies Drew The Most Letters In 2016
Drug Compounding Can't Be Justified By Price, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS118766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel